Topics: Part D, Medicare, Medicare Monday
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
As we reflect on 10 years since the implementation of Medicare Part D, we’re taking a closer look at what was said in the early years after the law was passed and what actually happened. Over the next few weeks, follow along for our then-and-now series on Medicare Part D success.
Today we’re looking at two claims around Part D costs and beneficiary premiums.
Tune in next week for our next Part D Then and Now.
Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience included leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.
Topics: Part D, Medicare, Medicare Monday
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004